Laxmi Dental Ltd

Laxmi Dental Ltd has received approval from both the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) for the listing of 7,911 equity shares. These shares are being issued under the Laxmi Dental Employee Stock Option Scheme 2024. The approvals signify the completion of the ESOP allotment process and allow for the trading of these new shares on both exchanges, effective September 18, 2026. This move is part of the company's strategy to incentivize and retain its employees through equity-based compensation.

Laxmi Dental Limited has announced its 22nd Annual General Meeting (AGM) scheduled for Friday, September 25, 2026, at 10:00 am IST. The meeting will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company has also submitted its Annual Report for the Financial Year ended March 31, 2026, in compliance with SEBI regulations. Both the AGM notice and the Annual Report are available on the company's website. The report highlights the company's market capitalization of INR 9,060.51 million as of March 31, 2026, and details its strategic focus on pioneering the digital future of dentistry.

Laxmi Dental Limited has announced its 22nd Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 10:00 am IST. The meeting will be conducted via video conferencing (VC) or other audio-visual means (OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of Mr. Rajesh Vrajlal Khakhar as a Director, and a special resolution to approve variations in the objects and timeline for the utilization of Initial Public Offering (IPO) proceeds. The company has provided a detailed breakdown of IPO fund utilization, highlighting reallocations for new capital expenditure objects.

Laxmi Dental Limited has received approval from both the National Stock Exchange (NSE) and BSE Limited (BSE) for the listing and trading of 59,360 equity shares. These shares, with a face value of Rs. 2 each, were issued under the Laxmi Dental Employee Stock Option Scheme 2024. The approvals were granted on August 31, 2026, with trading commencing on September 1, 2026. The company has provided the necessary documentation and will make the approval letters available on its website.

Laxmi Dental Ltd announced the allotment of 7,911 equity shares under its ESOP 2024 scheme, increasing its paid-up capital. The company also proposed a variation in the objects of its Initial Public Offering (IPO) proceeds and an extension of the utilization timeline, subject to shareholder approval. Consequently, the trading window for designated persons and their relatives will be closed from August 27, 2026, until 48 hours after the declaration of voting results for the upcoming shareholders' meeting. The Board meeting where these decisions were made concluded on August 27, 2026.

Laxmi Dental Limited's Board of Directors met on August 27, 2026, approving the allotment of 7,911 equity shares under its ESOP 2024 scheme. This allotment increases the company's paid-up equity share capital. The board also proposed a variation in the objects of its Initial Public Offering (IPO) proceeds and an extension of the utilization timeline, subject to shareholder approval. Consequently, the trading window for designated persons will remain closed from August 27, 2026, until 48 hours after the shareholders' meeting results are declared.

Laxmi Dental Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported a record-high quarterly revenue of ₹747.0 crore, marking a 13.9% year-on-year growth. EBITDA stood at ₹143.6 crore with an EBITDA margin of 19.2%. Profit After Tax (PAT) was ₹103.2 crore, resulting in a PAT margin of 13.8%. The company highlighted strong performance in its Dental Laboratory and Aligner Solutions businesses, with international operations showing significant growth. Strategic initiatives include strengthening U.S. leadership and expanding support facilities in India to enhance market penetration and customer service.

Laxmi Dental Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. Issued by ICRA Limited, the report confirms that the utilization of IPO proceeds is in line with the objects stated in the offer document. There has been no material deviation observed. The report covers the period up to June 30, 2026, and details the allocation of funds towards various objectives including repayment of borrowings, investment in subsidiaries, and capital expenditure for new machinery. The company's IPO, which closed on January 15, 2025, raised approximately ₹698.058 Crore (including OFS). The net proceeds available for utilization were ₹128.170 Crore.

Laxmi Dental Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the acquisition of land in Palghar for INR 6.21 crore and the allotment of 59,360 equity shares under its ESOP scheme. The company also noted the surrender of 1,636 ESOPs by an employee. The financial results were declared on a standalone and consolidated basis.

Laxmi Dental's consolidated Q1FY27 revenue hit a record ₹74.70 Cr, up 13.9% YoY and 1.0% QoQ, while consolidated PAT (including JV share) rose faster at ₹10.32 Cr, up 23.8% YoY and 2.2% QoQ; basic EPS was ₹1.87 versus ₹1.53 a year ago. No exceptional items hit either the current or year-ago quarter. The profit outperformance came from margin expansion: EBITDA-level margin (segment result/revenue) rose to 19.2% from 18.2% YoY, and net margin to 13.4% from 12.4% YoY. The driver was a segment mix shift — Aligners revenue grew 29.1% YoY to ₹24.17 Cr with its segment result up ~187% to ₹6.53 Cr (margin near 27%, roughly doubled from a year ago), while the larger Laboratory business, though still growing revenue 12.8% YoY to ₹50.28 Cr, saw its segment result fall 24.2% YoY to ₹7.70 Cr. Overall margin expansion this quarter therefore masks softness on the lab side. No quarter-specific analyst estimate for Q1FY27 could be located (only a broader FY26 full-year consensus revenue figure near ₹296 Cr exists), so the print cannot be graded against street numbers this quarter. Against management's own May-2026 concall commentary — a past growth benchmark of "16% in a challenging year" and long-term margin targets of EBITDA 18-20%, gross 75-80% and PAT 13-15% with no committed timeline — margins are already tracking within those bands while the 13.9% YoY revenue growth trails the cited 16% reference, a mixed read. Standalone PAT was ₹6.17 Cr against the consolidated ₹10.32 Cr, with subsidiaries and JV shares making up the difference. The same board meeting also noted a Letter of Intent to acquire land at Palghar for ₹6.21 Cr (₹51 Lakh advance paid) toward factory expansion and approved allotment of 59,360 ESOP shares; IPO proceeds utilisation stood at ₹77.97 Cr of the ₹128.17 Cr raised, with ₹50.20 Cr still parked in fixed deposits pending an extension for deployment. Management's press release called this the "highest-ever quarterly" revenue level, attributing performance to broad-based momentum in the Dental Laboratory and Aligner Solutions businesses and flagging profitability improvement "largely on account of a better product mix" — consistent with the segment data showing Aligners driving this quarter's margin gain. Management also cited efforts to strengthen on-ground US leadership.